UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2024

Commission File Number: 001-41842

 

 

Abivax SA

(Translation of registrant’s name into English)

 

 

7-11 boulevard Haussmann

75009 Paris, France

+33 (0) 1 53 83 08 41

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

 

 

 

On December 23, 2024, Abivax SA (the “Company”) announced the resignation of Dr. Philippe Pouletty as a member of the Company’s Board of Directors, effective on December 31, 2024. Dr. Pouletty’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

On December 23, 2024, the Company published a press release announcing the resignation described above. A copy of the press release is furnished as Exhibit 99.1 to this Report on Form 6-K and is incorporated herein by reference.

 

Exhibit Index
Exhibit 99.1		Press Release, dated December 23, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

				Abivax SA
				(Registrant)
Date: December 23, 2024				/s/ Marc de Garidel
				Marc de Garidel
				Chief Executive Officer